Study the effect of endocannabinoid system on rat behavior in elevated plus-maze

Basic and Clinical Neuroscience

Volumn 6, Issue 3, 2015, Pages 147-153

  Komaki, Alireza ^a,b   Hashemi Firouzi, Nasrin ^a   Shojaei, Shiva ^b   Souri, Zobin ^b   Heidari, Somayeh ^b   Shahidi, Siamak ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anxiety; Cannabinoids; Rat; URB 597

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; LOCOMOTION; MALE; NONHUMAN; PROTEIN DEGRADATION; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; TRANQUILIZING ACTIVITY;

EID: 84937213068     PISSN: 2008126X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Adams, I. B., Martin, B. R. (1996). Cannabis: Pharmacology and toxicology in animals and humans. Addiction, 91(11), 1585-1614.
2. Arévalo, C., de Miguel, R., Hernández-Tristán, R. (2001). Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology Biochemistry and Behavior, 70(1), 123-131.
3. Berrendero, F., Maldonado, R. (2002). Involvement of the opioid system in the anxiolytic-like effects induced by ?9- tetrahydrocannabinol. Psychopharmacology, 163(1), 111-117.
4. Bisogno, T., Di Marzo, V. (2007). Short-and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacological Research, 56(5), 428-442.
5. Breivogel, C. S., Childers, S. R. (1998). The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Disease, 5(6), 417-431.
6. Chegini, H. R., Nasehi, M., Zarrindast, M. R. (2014). Differential role of the basolateral amygdala 5-HT3 and 5-HT4 serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice. Behavioural Brain Research, 261, 114-126.
7. Chhatwal, J. P., Davis, M., Maguschak, K. A., Ressler, K. J. (2005). Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology, 30(3), 516-524.
8. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A., Axelrod, J. (1993). Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacology Biochemistry and Behavior, 46(4), 967-972.
9. Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121-130.
10. Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry, 75(6), 2434-2444.
11. Falenski, K. W., Thorpe, A. J., Schlosburg, J. E., Cravatt, B. F., Abdullah, R. A., Smith, T. H., et al. (2010). FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after ?9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology, 35(8), 1775-1787.
12. Gaetani, S., Cuomo, V., Piomelli, D. (2003). Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends in Molecular Medicine, 9(11), 474-478.
13. Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., et al. (2009). The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. International Review of Neurobiology, 85, 57-72.
14. Giuliani, D., Ferrari, F., Ottani, A. (2000). The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacological Research, 41(1), 45-51.
15. Gobira, P. H., Aguiar, D. C., Moreira, F. A. (2013). Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze. Pharmacology Biochemistry & Behavior, 110, 33-39.
16. Hall, W. (1994). Health and Psychological Effects of Cannabis Use. Current Issues in Criminal Justice, 6(2), 208.
17. Haller, J., Varga, B., Ledent, C., Barna, I., Freund, T. F. (2004). Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. European Journal of Neuroscience, 19(7), 1906-1912.
18. Haller, J., Varga, B., Ledent, C., Freund, T. F. (2004). CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behavioural Pharmacology, 15(4), 299-304.
19. Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., De Costa, B. R., et al. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences, 87(5), 1932-1936.
20. Hollister, L. E. (1986). Health aspects of cannabis. Pharmacological Reviews, 38(1), 1-20.
21. Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine, 9(1), 76-81.
22. Lafenêtre, P., Chaouloff, F., Marsicano, G. (2007). The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacological Research, 56(5), 367-381.
23. Lister, R. G. (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 92(2), 180-185.
24. Long, L. E., Chesworth, R., Huang, X. F., McGregor, I. S., Arnold, J. C., Karl, T. (2010). A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology, 13(7), 861-876.
25. Marco, E., Perez-Alvarez, L., Borcel, E., Rubio, M., Guaza, C., Ambrosio, E., et al. (2004). Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behavioural Pharmacology, 15(1), 21-27.
26. Martin, M., Ledent, C., Parmentier, M., Maldonado, R., Valverde, O. (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl), 159(4), 379-387.
27. Micale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F., et al. (2009). Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology, 34(3), 593-606.
28. Moreira, F. A., Aguiar, D. C., Guimarães, F. S. (2006). Anxiolytic- like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(8), 1466-1471.
29. Moreira, F. A., Aguiar, D. C., Guimarães, F. S. (2007). Anxiolytic- like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology, 52(3), 958-965.
30. Moreira, F. A., Kaiser, N,. Monory, K., Lutz, B. (2008). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology, 54(1), 141-150.
31. Naderi, N., Haghparast, A., Saber-Tehrani, A., Rezaii, N., Alizadeh, A. M., Khani, A., et al. (2008). Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacology Biochemistry & Behavior, 89(1), 64-75.
32. Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., Lichtman, A. H. (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology, 192(1), 61-70.
33. Navarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. A., Carrera, M. R. A., et al. (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport, 8(2), 491-496.
34. Patel, S., Hillard, C. J. (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. Journal of Pharmacology and Experimental Therapeutics, 318(1), 304-311.
35. Pellow, S., Chopin, P., File, S. E , & .Briley, M. (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14(3), 149-167.
36. Pertwee, R. G. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opinion on Investigational Drugs, 9(7), 1553-1571.
37. Roohbakhsh, A., Moghaddam, A. H., Massoudi, R., Zarrindast, M. R. (2007). Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clinical and Experimental Pharmacology and Physiology, 34(3), 223-229.
38. Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Vigano, D., Marras, E., et al. (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cerebral Cortex, 18(6), 1292-1301.
39. Steel, Z., Marnane, C., Iranpour, C., Chey, T., Jackson, J. W., Patel, V., et al. (2014). The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. International Journal of Epidemiology, 43(2), 476-93.
40. Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., Manzanares, J. (2004). Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology, 46(7), 973-66.
41. Viveros, M., Marco, E. M., File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior, 81(2), 331-342.
42. Viveros, M. P., Marco, E. M., File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry & Behavior, 81(2), 331-342.
43. Viveros, M. P., Marco, E. M., Llorente, R., Lopez-Gallardo, M. (2007). Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plasticity, 2007, 52908.
44. Zarrindast, M. R., Mahboobi, S., Sadat-Shirazi, M.-S., Ahmadi, S. (2011). Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. Journal of Psychopharmacology, 25(1), 131-140.
45. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl), 76(3), 245-250.